Compare Enveric Biosciences Inc (ENVB) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Paycom Software Inc — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Paycom Software Inc trades at $151.74 (market cap $6.75B). The key difference: Paycom Software Inc is far larger — about 1268.8× Enveric Biosciences Inc's market cap, and Paycom Software Inc pays a 1.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PAYC | |
|---|---|---|
Market Cap | $5.32M | $6.75B |
Sector | Health | Technology |
52-Week High | $17.40 | $238.80 |
52-Week Low | $1.28 | $113.59 |
Enterprise Value | $408.82K | $7.36B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Paycom Software (PAYC) trades at $152.79, up 6.35% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $151.00. Recent earnings beat expectations in Q4 2025 and Q1 2026, with revenue growing to $2.05 billion in 2025. The company maintains strong profitability, including a 22.44% net income margin and 37.15% ROE, while launching new tools like Asset Management to drive growth.
Outlook is cautiously optimistic, with potential upside to the $183.00 high target, supported by solid fundamentals and product innovation. Risks include competitive pressures in HCM software and reliance on steady revenue growth. Investors should weigh the stock's current valuation against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
